|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.965 USD | -0.93% |
|
-2.55% | -20.08% |
June 21 (Reuters) - GlaxoSmithKline Plc:
* GSK AND VIR BIOTECHNOLOGY ANNOUNCE CONTINUING PROGRESS OF THE COMET CLINICAL DEVELOPMENT PROGRAMME FOR SOTROVIMAB
* ANALYSIS CONFIRMS SOTROVIMAB REDUCES HOSPITALISATION, RISK OF DEATH IN ADULTS WITH MILD-TO-MODERATE COVID-19 AT HIGH RISK OF PROGRESSION TO SEVERE DISEASE
* FURTHER RESEARCH INITIATED TO EVALUATE INTRAMUSCULAR ADMINISTRATION OF SOTROVIMAB FOR EARLY TREATMENT OF MILD-TO-MODERATE COVID-19 Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| -20.08% | 1.09B | |
| +4.09% | 43.84B | |
| +46.73% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
VIR BIOTECHNOLOGY, INC. 
